
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The complex packaging and logistics required for personalized medicine pose significant challenges, but proactive planning can help ensure success.
Kirk Randall of Cryoport shares insights into the complexity of cold chain logistics for advanced therapeutics (e.g. cell and gene therapies), and what is needed to ensure that logistics does not impede clinical trial or commercial success. Included are discussions of skill sets to look for in contract partners.
Download
.
over 9 years ago
Clean, Disinfect, and Validateover 9 years ago
Kill the Bioburden, Not the Biological Indicatorover 9 years ago
Ensuring the Biological Integrity of Raw Materialsover 9 years ago
Getting Biopharmaceutical Tech Transfer Right the First Timeover 9 years ago
Case Study: Retrofitting Two New High-Purity Water Systemsover 9 years ago
Single-Use Bioreactors Have Reached the Big Timeover 9 years ago
Parallel Processingover 9 years ago
Cost Considerations Drive Lean Technology in Biomanufacturing





